Abstract
Concerning small-cell lung cancer (SCLC), the addition of immune checkpoint inhibitors to first-line chemotherapy represents the first significant improvement of systemic therapy in several decades. However, only a small proportion of patients with SCLC benefit from immune checkpoint inhibitors. In contrast, biomarkers that predict efficacy of immunotherapy are not well characterized in SCLC. In this observational cohort study, we performed a basal assessment of circulating immune cells, evaluating the association with progression free survival (PFS) and overall survival (OS) in patients treated with IMpower 133 schedule.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
